<DOC>
	<DOCNO>NCT01205711</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan hydrochloride , fluorouracil , leucovorin calcium , work different way stop growth tumor cell , either kill cell stop dividing . Zibotentan may effective treat metastatic colorectal cancer respond oxaliplatin . It yet know whether combination chemotherapy effective give without zibotentan treat metastatic colorectal cancer . PURPOSE : This randomized phase II trial study give irinotecan hydrochloride together fluorouracil leucovorin calcium see well work give without zibotentan treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Hydrochloride , Fluorouracil , Leucovorin Calcium With Without Zibotentan Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish anti-tumor activity combination irinotecan hydrochloride , fluorouracil , leucovorin calcium ( FOLFIRI ) zibotentan ( FOLFERA ) measure progression-free survival ( time-to-event ) patient metastatic colorectal cancer failure oxaliplatin-containing chemotherapy . Secondary - To determine toxicity profile FOLFERA maintenance zibotentan patient . - To determine feasibility use regimen patient . - To collect tumor blood sample future translational work , include investigate endothelian A receptor ( ETAR ) expression , k-RAS/b-RAF status alteration relevant pathway Akt , MAPK/ERK . OUTLINE : This multicenter study . Patients stratify accord study site . Patients randomize 1 2 treatment arm . - Arm A : Patients receive irinotecan hydrochloride IV 1 hour leucovorin calcium IV 2 hour day 1 ; fluorouracil IV 46 hour begin day 1 ; oral placebo tablet daily day 1-14 . Treatment repeat every 14 day 12 course absence disease progression unacceptable toxicity . Patients achieve least stable disease receive oral placebo alone daily absence disease progression unacceptable toxicity . - Arm B : Patients receive irinotecan hydrochloride IV 2 hour , leucovorin calcium IV 2 hour day 1 ; fluorouracil IV 46 hour begin day 1 ; oral zibotentan daily day 1-14 . Treatment repeat every 14 day 12 course absence disease progression unacceptable toxicity . Patients achieve least stable disease receive oral zibotentan alone daily absence disease progression unacceptable toxicity . Blood tissue sample collect periodically pharmacogenetic , translational , biomarker correlative study . After completion study therapy , patient follow 30 day every 12 week 1 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal cancer Metastatic disease bone metastases Must progress within 6 month adjuvant oxaliplatincontaining chemotherapy significant ongoing toxicity ( exclude grade 1 neurotoxicity ) Measurable disease RECIST criteria No known brain leptomeningeal metastases Stable disease follow surgical resection radiosurgery oligometastases allow PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week Hemoglobin ≥ 9.0 g/dL ( prior transfusion ) OR ≥ 10.0 g/dL ( transfusion within past 4 week ) Absolute neutrophil count ≥ 1.5 time 10^9/L Platelet count ≥ 100 time 10^9/L Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN liver metastasis ) Creatinine clearance ≥ 50 mL/min Negative pregnancy test Not pregnant nursing Fertile patient must use effective doublemethod contraception 3 month ( female ) 2 month ( male ) completion study treatment No active infection serious concurrent medical condition No significant cardiovascular disease include follow : History NYHA class IIIV congestive heart failure require therapy History unstable angina pectoris myocardial infarction within past 6 month Severe valvular heart disease Ventricular arrhythmia require treatment Prolonged QTc interval &gt; 470 msec No concurrent medical condition , investigator 's judgement , substantially increase risk associate patient 's participation study , potentially hamper compliance study protocol followup schedule No psychiatric disorder alter mental status preclude understand informed consent process and/or compliance study protocol No gastrointestinal disorder likely interfere absorption study drug ( e.g. , partial bowel obstruction malabsorption ) No known serological positivity hepatitis B hepatitis C No immunocompromised patient ( e.g. , known serological positivity HIV ) No prior current malignant disease likely interfere protocol treatment comparison PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior zibotentan irinotecan hydrochloride More 4 week since prior chemotherapy , radiotherapy ( except palliative reason ) , endocrine therapy , immunotherapy No 1 prior course chemotherapy metastatic disease No prior extensive radiotherapy ( i.e. , likely deplete bone marrow reserve ) At least 4 week since prior major surgery recover Concurrent corticosteroid allow provide dose stable 4 week alter first 15 day study No concurrent warfarin Low molecular weight heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>